CaroGen
CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
Launch date
Employees
Market cap
-
Enterprise valuation
€545—818k (Dealroom.co estimates Sep 2013.)
Hamden Connecticut (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$150k | Seed | ||
N/A | Spinout | ||
$1.4m | Grant | ||
* | $3.0m | Grant | |
* | $6.8m | Grant | |
Total Funding | €10.3m |
Recent News about CaroGen
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.